The steadily increasing number of Celsion conference appearances may serve to increase added research coverage of Celsion over time. Celsion addresses so many of the major forms of Cancer and is an incredibly cheap stock when measured against the huge population of potential cancer victims which Celsion may help to cure. Because these statistics are so dramatic, every new research report on Celsiom appearing in recent years has been a positive recommendation to Buy the stock. This trend should contine until the stock is at least in the $20s or $30s. This is a very significant, very positive factor for Celsion investors. The company is finally beginning to gain widespread recognition in the Biotech/Biopharma Wall Street research community. Companies are only invited to the conferences which Celsion is participating in currently, after approval and signoff by the brokerage firm's analyst covering the Biotech/Biopharma sector. The Needham & Company Annual Conference will be another event early in January. Best, Mojo.